
Definitive Radiotherapy for the Treatment of Non-Small Cell Lung Cancer in Patients Aged 70 Years and Older
Background: The factors affecting survival were evaluated in patients aged ≥ 70 years with Non-Small Cell Lung Cancer (NSCLC) treated with definitive Radiotherapy (RT).
Methods: Between January 1996 and April 2012, 52 patients were treated. The median age was 73 (range 70-80) and 73% and 75% of patients with stage III according to AJCC 2002 and AJCC 2010 staging, respectively. Radiotherapy was performed median 6160 cGy (range: 3600-6660 cGy) and CHE were given 75% of the patients.
Results: Median follow-up was 12.5 (range: 2.5-103) months. Median overall (OS) and Disease-Free (DFS) Survival were 22 and 18.5 months, respectively. Radiotherapy related death was not observed. In Univariate analysis; AJCC 2002 stage I-II, RT dose, RT duration, for OS and RT dose, RT duration, neoadjuvant CHE ≤ 3 cycles, complete response, ≥ 4 cycles of CHE for DFS were significant (p <0.05). In multivariate analysis, RT duration > 49 days related with higher RT dose (≥ 60 Gy) were found a positive impact on OS (HR: 3.235, 95% CI: 1:25 to 8:32 p = 0.01).
Conclusion: In our study, elderly patients with NCSLC can be given ≥ 60 Gy without complications and was seen positively impact on survival.
Süreyya Sarıhan*1, Türkkan Evrensel2 and Deniz Sığırlı3